Teva Pharmaceutical Industries Limited (NYSE:TEVA) Sees Significant Growth in Short Interest

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report) was the recipient of a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 26,660,000 shares, a growth of 19.2% from the January 31st total of 22,360,000 shares. Based on an average daily volume of 11,930,000 shares, the short-interest ratio is currently 2.2 days.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 286,000 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the sale, the director now directly owns 695,000 shares in the company, valued at $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.55% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. FMR LLC lifted its stake in shares of Teva Pharmaceutical Industries by 30.7% in the fourth quarter. FMR LLC now owns 81,983,231 shares of the company's stock worth $1,806,910,000 after buying an additional 19,242,468 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd raised its holdings in Teva Pharmaceutical Industries by 12.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock worth $859,935,000 after acquiring an additional 4,418,961 shares during the period. Ion Asset Management Ltd. lifted its position in Teva Pharmaceutical Industries by 1.1% during the 4th quarter. Ion Asset Management Ltd. now owns 36,650,000 shares of the company's stock worth $807,766,000 after acquiring an additional 409,778 shares during the last quarter. Lingotto Investment Management LLP boosted its holdings in Teva Pharmaceutical Industries by 2.6% during the fourth quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company's stock valued at $599,320,000 after acquiring an additional 688,862 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. grew its position in shares of Teva Pharmaceutical Industries by 2.2% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company's stock valued at $573,822,000 after purchasing an additional 569,412 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

Remove Ads

Analyst Ratings Changes

A number of analysts have recently weighed in on TEVA shares. Piper Sandler upped their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. StockNews.com downgraded Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research note on Friday. Bank of America decreased their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research note on Thursday. UBS Group dropped their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research report on Thursday, January 30th. Finally, Barclays lowered their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $23.43.

Teva Pharmaceutical Industries Stock Down 4.4 %

Teva Pharmaceutical Industries stock traded down $0.68 during trading hours on Monday, hitting $14.69. The company had a trading volume of 13,334,604 shares, compared to its average volume of 12,811,797. Teva Pharmaceutical Industries has a fifty-two week low of $12.51 and a fifty-two week high of $22.80. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The firm has a market capitalization of $16.65 billion, a P/E ratio of -10.13, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82. The firm's fifty day moving average is $18.85 and its 200-day moving average is $18.38.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, research analysts forecast that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.